S717 The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced Therapy
David T. Rubin(University of California System), Julián Panés(Hospital Clínic de Barcelona), Tadakazu Hisamatsu(Kyorin University), Axel Dignaß(Goethe University Frankfurt), Rebbecca Wilson(Janssen (United States)), Jessica R. Allegretti(Brigham and Women's Hospital), Kuan‐Hsiang Gary Huang(Janssen (United States)), Mary Kavalam(Johnson & Johnson (United States)), Emese Mihály(Semmelweis University), Matthew Germinaro(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k